Scroll To Top
Search by Speciality

16th Annual World Congress Insulin Resistance Diabetes & Cardiovascular Disease (WCIRDC)

From 450 to 550 USD
Event Preview
EXPIRED
This event
is Finished
Title: 16th Annual World Congress Insulin Resistance Diabetes & Cardiovascular Disease (WCIRDC)
Specialty: Internal Medicine
Dates: From Nov, 29, 2018 to Dec, 1, 2018
Location: Seattle, USA
Type: Congress
Registration Cost: From 450 to 550 USD
Event Tools
  • Add to Favorites
  • Claim this event
Add to my Calendar
  • Scientific Programm
  • Online registration
  • Exhibition floorplans
  • Sponsorship &
    Exhibition consensus
  • Virtual Booths
Nov
Weather Info (monthly averages) Max Temperature: C / F Min Temperature: C / F The above data in our Weather Info table are temperature predictions for the date of the medical event for Seattle, Usa.
General Info
Event Venue:

TBD

Seattle, USA Visit the Venue to read more
Currency:
USD
Concerned Audience:
  • Medical_Professionals
  • Medical_students
  • Nurses
Event Overview
Welcome message:

16th Annual World Congress Insulin Resistance Diabetes & Cardiovascular Disease (WCIRDC) is organized by The Metabolic Institute of America (TMIOA) and will be held during Nov 29 - Dec 01, 2018 at Los Angeles, California, United States of America.


The target audience for this medical event is cardiologists, endocrinologists, gastroenterologists, oncologists, internists, diabetologists, OBGYNs, pediatricians, dietitians, nurse practitioners, pharmacists, and any other health care professionals who are interested in insulin resistance, diabetes, obesity, cardiovascular disease, and multiple metabolic mechanisms’ effects on health and society, as well as on potential treatment and prevention. This CME Conference has been approved for a maximum of 28 AMA PRA Category 1 Credits.


Course Objectives are :

The program is designed to evaluate both the clinical and basic science aspects of diabetes, obesity, dyslipidemia and CVD, by focusing on insulin resistance, hyperinsulinemia, fat cells, the heart, the kidneys, and energy metabolism. The goal is to understand its pathophysiology, and to develop appropriate comprehensive clinical management plans.

Upon completion of this meeting, participants should be able to:

• Provide comprehensive management of diabetes, by addressing obesity, hypertension, dyslipidemia, and cardiovascular risks.

• Discuss the role of obesity in the development of cardiometabolic conditions

• Discuss the role of incretins in the management of obesity, diabetes, and prevention of CVD

• Be aware of the results of cardiovascular outcome trials and understand the potential role of SGLT2i & GLP1ra in managing Diabetes and CVD

• Evaluate the extent of macrovascular and microvascular disease in diabetes and obesity

• Address the risks of heart disease in patients with diabetes

• Explain the role of lipids, in particular low-density lipoprotien (LDL-C) and non- HDL-C, in the development of atherosclerosis

• Examine the role of PCSK9 and the newly developed monoclonal antibodies- the PCSK9 inhibitors in LDL homeostasis and on the contemporary approaches to management and prevention of CVD

• Describe contemporary approaches to congestive heart failure

• Explain the relationship of the kidney to insulin resistance, diabetes and CVD

• Explain the pathophysiology and complications of fatty liver disease and its relationship to diabetes and CVD

• Discuss the role of SGLT2i in the management of diabetes its potential role beyond glycemia and known complications.

• Evaluate bariatric surgery and newly-developed procedures, as well as devices and their effect on weight loss and hormones, and their long-term outcomes

Speakers/Faculty:

Yehuda Handelsman, MD, FACP, FNLA, MACE Chair


Chair & Program Director, 2nd HiD & 16th Annual WCIRDC


Medical Director & Principal Investigator, Metabolic Institute of America 


Chair & Founder, International Committee for Insulin Resistance


Chair & Founder, International Lipid Forum


Tarzana, California


King, George L 2.jpg

George L. King, MD

Chief Scientific Officer,


Joslin Diabetes Center

Professor of Medicine and Ophthalmology

Harvard Medical School

Boston, Massachusetts


Bergman, Richard.jpg

Richard N. Bergman, PhD

Alfred Jay Firestein Chair in Diabetes Research

Professor, Department of Biomedical Sciences, Cedars-Sinai

Director, Sports Spectacular Diabetes and Obesity Wellness and Research Center (SSDOWRC)

Professor-in-Residence, Department of Medicine, UCLA

Los Angeles, California


Klein, Samuel.jpg

Samuel Klein, MD

William H. Danforth Professor of Medicine and Nutritional Science

Director, Center for Human Nutrition

Chief, Division of Geriatrics & Nutritional Science

Washington University School of Medicine

St. Louis, Missouri

Registration Needs updating Register Now
Currency:

USD

Registration Cost
Type
Early Registration

2018-08-26
Late Registration From: 2018-08-27 To: 0--
On site Registration
Registration
450
550
0

Group Registrations:

Group registrations not allowed

Accompanying Persons:

Accompanying persons not allowed

Registration Documents:
Letter of invitation:
We don’t provide letter of invitation
Letter of confirmation:
We don’t provide Letter of Confirmation
Proof of professional / educational status:
We don’t need Proof of professional/educational status
Online Abstract Submission:

We don’t accept Online Abstracts

Accommodation
Accommodation:

The 16th WCIRDC will be held at the Hilton Universal City Hotel in Los Angeles, California from November 29 - December 1, 2018.

Special room rates of $214 per night are available for all WCIRDC attendees. 

To book rooms at the Hilton, please go here: https://book.passkey.com/e/49638626 

 

OR call (818) 623-1434 and reference group name: WCIRDC

Group room reservations are also available. To book a block of rooms for your group of 15 or more, please contact us at info@tmioa.com or (818) 342-1889.

We hope to see you there!

Hilton Universal City Hotel

Address: 555 Universal Hollywood Dr, Universal City, CA 91608

Phone: (818) 506-2500

Scientific Content Up to Date
Submission Info

Accepted  Abstracts will be published in Endocrine Practice, the official journal of AACE.


Accepted  Abstracts will  have a poster presentation at the meeting.


Top Abstracts will be selected for oral presentation at the meeting.


In some cases, the committee may consider Late Breaking Abstracts for oral presentation.


 


Abstract Submission & Topics:



Clinical aspects of insulin resistance in childhood, adolescence and/or adulthood pertaining to:


Diabetes, obesity, dyslipidemia, hypertension, cardiovascular disease, malignancy, liver disease, renal disease, gonadal dysfunction, sleep disorders such as obstructive sleep apnea.


 


Basic science:



Mechanisms of insulin resistance, inflammation, endothelial and vascular dysfunction, metabolic dysfunction of centers such as the beta cell, adipocyte, gut, and brain.



Guidelines:



Abstracts should address either clinical or basic science aspects of insulin resistance, in fields such as diabetes, obesity, and cardiovascular disease.  Investigations of overall pathophysiology and/or effects on key metabolic centers such as the beta cell, adipocyte, gut, and brain would be of interest, as would be studies of inflammation and of endothelial or other vascular dysfunction. Clinical topics may include any aspect of insulin resistance in childhood, adolescence and/or adulthood in relationship to the causation and/or natural history of obesity, diabetes, hypertension, dyslipidemia, cardiovascular disease, renal disease, gonadal dysfunction (including both PCOS and male hypogonadism), gestational diabetes, other endocrine abnormality, liver disease (NAFLD), malignancy, and sleep disorders such as obstructive sleep apnea.


The interests of the Congress include multi-hormonal aspects of obesity, incretins and other gut hormonal contributions to energy balance, and circadian rhythm as it relates to these metabolic mechanisms. Basic science studies should include those with specific relationship to insulin action and its regulation at the cellular, organ, or whole body level.



To demonstrate their conformity to this guideline, authors are encouraged to include a brief clarification of the relationship of their topic to insulin resistance and/or to the above metabolic processes.


In addition:



Scientific materials presented at the 16th Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (2018) must not have been published or presented prior to November 29, 2018, other than in abstract form.



All abstracts must be submitted electronically on a Microsoft Word document of no more than 250 words. Graphs are allowed not to exceed 8.5”  X 11” word document   (No PDF documents will be accepted, or any submissions by fax or mail.) For sample formatting, please click here.


All materials must arrive on or before the abstract deadline noted above.


Notification for acceptance will be e-mailed as soon as the committee accepts the abstract.


Authorship on multiple abstracts is permitted.


All submitted materials will be graded by the scientific planning committee, The International Committee for Insulin Resistance.


Abstracts may be submitted for poster presentation. If selected for poster presentation, the author is required to register for the Congress and to be present during the poster sessions. Awards will be given for the highest-ranking abstracts. The award levels are: Gold, Silver, Bronze, and honorable mention. The authors of the winning abstracts will orally present their research findings during the Plenary Sessions in a ten minute presentation, to be followed by a five minute period of discussion.


If selected for oral presentation, an author is required to register for the Congress and to be prepared for the oral presentation with a PowerPoint presentation.  Abstracts must be accompanied by a statement from the authors agreeing that, if chosen, they will prepare a poster presentation, and that, if awarded a high ranking, they will prepare an oral presentation.


Abstracts will be published in: Endocrine Practice.Editor-in-Chief – Derek Leroith, MD, PhD “Endocrine Practice is a peer-reviewed journal published six times a year, and is the official journal of the American Association of Clinical Endocrinologists (AACE). The first issue of Endocrine Practice was published in 1995. The primary mission of Endocrine Practice is to enhance the health care of patients with endocrine diseases through continuing education of practicing endocrinologists.”

Abstract submission deadline 2018-10-22
Sponsors Exhibitors
General Info

Contact No.: 818-342-1889

Email: info@tmioa.com

Contact
Organising Agency

Contact No.: 818-342-1889

Email: info@tmioa.com

Official Event Webpage
Event map
Revelant Events